Drug and Alcohol Rehabilitation: Perfusing Chemotherapy by Percutaneous Lung Puncture in the Treatment of Extensive Drug Resistant Pulmonary Tuberculosis.
Perfusing chemotherapy by percutaneous lung puncture in the treatment of extensive drug resistant pulmonary tuberculosis.
Filed under: Drug and Alcohol Rehabilitation
J Thorac Dis. 2012 Dec; 4(6): 624-8
Yang SH, Zhan P, Sun M, Zhang YP, Ma NL
Although progress has been made to reduce global incidence of drug-susceptible tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) during the past decade threatens to undermine these advances. XDR-TB has been found to be associated with scarce therapeutic options and high mortality rates. We describe the first case of XDR-TB cured by percutaneous lung puncture and with post-hospital 4 years follow-up involving radiologic imaging and septum smear and TB culture. We also review the epidemiology, diagnosis and treatment of tuberculosis all the world.
HubMed – drug
Comparison of the lung function change in patients with COPD and bronchial asthma before and after treatment with budesonide/formoterol.
Filed under: Drug and Alcohol Rehabilitation
J Thorac Dis. 2012 Dec; 4(6): 583-7
Gao SY, Huang JQ, Luo YF, Li ZP, Xie CM, Guo YB
This study investigated the rapid onset of bronchodilation effect and compared lung function changes following budesonide/formoterol (Symbicort Turbuhaler®) inhalation in Chinese patients with moderate-severe chronic obstructive pulmonary disease (COPD) and bronchial asthma.In this open-label, parallel-group clinical study, patients eligible for study were divided into COPD group (n=62, mean age 68.16±8.75 years) and asthma group (n=30, mean age 45.80±12.35 years). Lung function tests (include FEV1, FVC, FEV1/FVC, and IC) were performed at baseline (t=0 min time point, value before inhalation of budesonide/formoterol), and then eligible patients received two inhalations of budesonide/formoterol (160/4.5 ?g). Lung function tests were reassessed at t=3, 10 and 30 min time point. The primary end-point was lung function change 3 min after drug inhalation, and the secondary end-points were comparison of the gas flow rate (?FEV1) and volume responses (?FVC, ?IC) between COPD and asthma patients after inhalation of budesonide/formoterol.Compared with the baseline, all patients significantly improved their lung function (included FEV1, FVC, FEV1/FVC, and IC) at 3 min (P<0.05). Greater bronchodilation efficacy was found in the asthma group compared with the COPD group (P<0.05). In the asthmatic patients, the curves of FEV1, FVC, FEV1/FVC, IC, showed improvement with an ascending trend at all time points from 3 to 30 min. Whereas in the COPD patients, only the curves of FEV1, FVC, IC showed similar pattern. We found that ?FVC was significantly higher than ?FEV1 in both groups (P<0.05), but no significant difference between ?IC and ?FEV1 (P>0.05). Compared with COPD group, asthma group had higher level of ?FEV1 and ?IC (P<0.05), but no significant difference for ?FVC can be found.Budesonide/formoterol has a fast onset of bronchodilation effect in patients with moderate-severe COPD and asthma. Greater efficacy was found in the asthma group compared with the COPD group. The gas flow rate and volume responses in patients with COPD differ from those with asthma after inhalation of Budesonide/formoterol. HubMed – drug
A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().
Filed under: Drug and Alcohol Rehabilitation
Medchemcomm. 2012 Dec; 3(12): 1505-1511
Mott BT, Cheng KC, Guha R, Kommer VP, Williams DL, Vermeire JJ, Cappello M, Maloney DJ, Rai G, Jadhav A, Simeonov A, Inglese J, Posner GH, Thomas CJ
Parasitic diseases continue to have a devastating impact on human populations worldwide. Lack of effective treatments, the high cost of existing ones, and frequent emergence of resistance to these agents provide a strong argument for the development of novel therapies. Here we report the results of a hybrid approach designed to obtain a dual acting molecule that would demonstrate activity against a variety of parasitic targets. The antimalarial drug amodiaquine has been covalently joined with a nitric oxide-releasing furoxan to achieve multiple mechanisms of action. Using in vitro and ex vivo assays, the hybrid molecule shows activity against three parasites – Plasmodium falciparum, Schistosoma mansoni, and Ancylostoma ceylanicum.
HubMed – drug
Malaria in children.
Filed under: Drug and Alcohol Rehabilitation
Mediterr J Hematol Infect Dis. 2012; 4(1): e2012073
Schumacher RF, Spinelli E
This review is focused on childhood specific aspects of malaria, especially in resource-poor settings. We summarise the actual knowledge in the field of epidemiology, clinical presentation, diagnosis, management and prevention.These aspects are important as malaria is responsible for almost a quarter of all child death in sub-Saharan Africa. Malaria control is thus one key intervention to reduce childhood mortality, especially as malaria is also an important risk factor for other severe infections, namely bacteraemia.In children symptoms are more varied and often mimic other common childhood illness, particularly gastroenteritis, meningitis/encephalitis, or pneumonia. Fever is the key symptom, but the characteristic regular tertian and quartan patterns are rarely observed. There are no pathognomonic features for severe malaria in this age group. The well known clinical (fever, impaired consciousness, seizures, vomiting, respiratory distress) and laboratory (severe anaemia, thrombocytopenia, hypoglycaemia, metabolic acidosis, and hyperlactataemia) features of severe falciparum malaria in children, are equally typical for severe sepsis.Appropriate therapy (considering species, resistance patterns and individual patient factors) – possibly a drug combination of an artemisinin derivative with a long-acting antimalarial drug – reduces treatment duration to only three days and should be urgently started.While waiting for the results of ongoing vaccine trials, all effort should be made to better implement other malaria-control measures like the use of treated bed-nets, repellents and new chemoprophylaxis regimens.
HubMed – drug
Cognitive Behavioral Therapy Session — Clarity Way Drug & Alcohol Rehab – At Clarity Way, our experienced therapists use an effective treatment technique called cognitive behavioral therapy to help our clients through drug and alcohol rehabilitation. Cognitive behavioral therapy is conducted through one on one verbal communication sessions. These sessions are focused on helping our clients address deep emotional issues and generate healthier thinking patterns. It’s crucial for the drug and alcohol rehabilitation process that our clients shift their thought processes away from negativity. Our dedicated staff provides individual cognitive behavioral therapy sessions on a consistent basis with our clients to help them achieve freedom from addiction. Through this process, clients learn about how their thinking patterns affect their everyday actions. Addressing the underlying emotional issues and thinking patterns of our clients has proven to be an incredibly successful form of therapy for drug and alcohol addiction. If you’d like to learn more about cognitive behavioral therapy at Clarity Way, or meet our caring staff, visit us online at www.ClarityWay.com. Our holistic approach to drug and alcohol rehab is why our clients have found so much success. Call us today at 1-877-548-4794 for more information!
Related Drug And Alcohol Rehabilitation Information…